Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL5466 Target Snapshot

Activin receptor type-2B · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
481Compounds
103Assays
3Approved Drugs
373.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Activin receptor type-2B shows approved-linked disease relevance led by bone disease. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q13705. Start with bone disease, then reuse UniProt Q13705 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with bone disease, then reuse UniProt Q13705 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
bone disease

Activin receptor type-2B shows approved-linked disease relevance led by bone disease. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with bone disease because it currently carries approved-linked support. Linked drugs include DIBOTERMIN ALFA. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Activin receptor type-2B as ChEMBL target CHEMBL5466, mapped to UniProt Q13705. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Activin receptor type-2B
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL5466
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q13705
Activin receptor type-2B
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Activin receptor type-2B is the right protein anchor across sources, using UniProt Q13705 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why bone disease is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameActivin receptor type-2B
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtQ13705
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelActivin receptor type-2B
UniProt AccessionQ13705
Component TypeProtein
Sequence Length512 aa

Activin receptor type-2B

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Activin receptor type-2B, mapped to UniProt Q13705. Sequence length is 512 aa.

Mapped IDQ13705
Review nameActivin receptor type-2B
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Activin receptor type-2B shows approved-linked disease relevance led by bone disease. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
bone disease
1 linked drug · 1 direct · 1 efficacy
Linked drugDIBOTERMIN ALFA
Approved-linked Approved
Fracture Fixation, Internal
1 linked drug · 1 direct · 1 efficacy
Linked drugDIBOTERMIN ALFA
Approved-linked Approved
Spinal Fusion
1 linked drug · 1 direct · 1 efficacy
Linked drugDIBOTERMIN ALFA
Approved-linked Approved
tibia fracture
1 linked drug · 1 direct · 1 efficacy
Linked drugDIBOTERMIN ALFA
Late clinical Phase III
inclusion body myositis
1 linked drug · 1 direct · 1 efficacy
Linked drugBIMAGRUMAB
Clinical signal Phase II
bone fracture
1 linked drug · 1 direct · 1 efficacy
Linked drugDIBOTERMIN ALFA
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with bone disease because it currently carries approved-linked support. Linked drugs include DIBOTERMIN ALFA. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasebone disease
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

3
Approved
3
Phase III
2
Phase II
4
Phase I
Assay Mix

Activity Type Distribution

IC5014.0
KD359.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5653589 8.52 Kd 3.019 Preclinical
CHEMBL1241674 8.12 Kd 7.6 Preclinical
CHEMBL386051 8.04 Kd 9.1 Preclinical
CHEMBL1808264 8.0 IC50 10.0 Preclinical
CHEMBL5591770 7.75 IC50 17.9 Preclinical
CHEMBL5595138 7.16 IC50 68.9 Preclinical
CHEMBL1090090 7.04 Kd 92.0 Clinical
CHEMBL2041933 6.6 Kd 253.0 Preclinical
CHEMBL1908397 6.43 Kd 370.0 Preclinical
CHEMBL403989 6.38 Kd 419.0 Clinical
Distribution

pChEMBL Value Distribution

13
5.0
10
5.5
5
6.0
1
6.5
2
7.0
1
7.5
3
8.0
1
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

DASATINIB
CHEMBL5416410
Approved 2006
Properties Compare Identifier
Assay Landscape

Assay Landscape

103
Total Assays
31
Tested Compounds
1
Assay Types
Binding — 103 assays, 31 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 80 23 6.1
assay format 21 1 5.5
cell-based format 1 0 —
subcellular format 1 7 5.8

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine